Adelia Therapeutics

Adelia's primary focus is on developing treatment regimens consisting of proprietary psychedelics and associated clinical protocols. This proprietary development strategy is based on the chemical modification of known and widely recognized psychedelics, significantly altering their pharmacokinetic properties without changing their therapeutic potential. These proprietary approaches aim to minimize variability between patients by better controlling drug metabolism while retaining efficacy, thereby collectively demonstrating the ability to produce more predictable and favorable patient outcomes.